Literature DB >> 14511953

DNA vaccine strategies: candidates for immune modulation and immunization regimens.

Nicole A Doria-Rose1, Nancy L Haigwood.   

Abstract

DNA vaccine strategies can differ greatly, with significant effects on the outcome of immunization. In this article, we discuss plasmid design strategies and vaccine regimens. Effectiveness against a pathogen can be affected by the choice of antigen and inclusion of multiple antigens. Gene expression and the resulting immune response can be improved by gene modification and choice of promoters. In designing vaccine regimens, one must consider further dose, timing of doses, adjuvants, and routes of vaccination. Many vaccines are enhanced by combining DNA with other vaccines in "prime-boost" regimens, in which the second vaccine is often a recombinant viral vector or purified protein subunit. Prime-boost vaccines including DNA can elicit immune responses that differ in magnitude, quality, and balance of cellular and humoral responses from those elicited by single components and thus provide further enhancement for DNA immunizations.

Mesh:

Substances:

Year:  2003        PMID: 14511953     DOI: 10.1016/s1046-2023(03)00135-x

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  29 in total

1.  The design and implementation of the immune epitope database and analysis resource.

Authors:  Bjoern Peters; John Sidney; Phil Bourne; Huynh-Hoa Bui; Soeren Buus; Grace Doh; Ward Fleri; Mitch Kronenberg; Ralph Kubo; Ole Lund; David Nemazee; Julia V Ponomarenko; Muthu Sathiamurthy; Stephen P Schoenberger; Scott Stewart; Pamela Surko; Scott Way; Steve Wilson; Alessandro Sette
Journal:  Immunogenetics       Date:  2005-05-14       Impact factor: 2.846

2.  DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge.

Authors:  Margherita Rosati; Agneta von Gegerfelt; Patricia Roth; Candido Alicea; Antonio Valentin; Marjorie Robert-Guroff; David Venzon; David C Montefiori; Phil Markham; Barbara K Felber; George N Pavlakis
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

3.  Generation of high-titer neutralizing antibodies against botulinum toxins A, B, and E by DNA electrotransfer.

Authors:  C Trollet; Y Pereira; A Burgain; E Litzler; M Mezrahi; J Seguin; M Manich; M R Popoff; D Scherman; P Bigey
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

4.  Protective efficacy of DNA vaccines encoding outer membrane protein A and OmpK36 of Klebsiella pneumoniae in mice.

Authors:  Prathiba Kurupati; N P Ramachandran; Chit Laa Poh
Journal:  Clin Vaccine Immunol       Date:  2010-11-03

Review 5.  Synthetic DNA vaccine strategies against persistent viral infections.

Authors:  Daniel O Villarreal; Kendra T Talbott; Daniel K Choo; Devon J Shedlock; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2013-05       Impact factor: 5.217

Review 6.  Nanocarriers targeting dendritic cells for pulmonary vaccine delivery.

Authors:  Nitesh K Kunda; Satyanarayana Somavarapu; Stephen B Gordon; Gillian A Hutcheon; Imran Y Saleem
Journal:  Pharm Res       Date:  2012-10-09       Impact factor: 4.200

7.  Cholera toxin B subunit acts as a potent systemic adjuvant for HIV-1 DNA vaccination intramuscularly in mice.

Authors:  Jue Hou; Ying Liu; Jenny Hsi; Hongzhi Wang; Ran Tao; Yiming Shao
Journal:  Hum Vaccin Immunother       Date:  2014-03-14       Impact factor: 3.452

Review 8.  DNA vaccines: roles against diseases.

Authors:  Kishwar Hayat Khan
Journal:  Germs       Date:  2013-03-01

9.  Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially.

Authors:  Franco Pissani; Delphine C Malherbe; Harlan Robins; Victor R DeFilippis; Byung Park; George Sellhorn; Leonidas Stamatatos; Julie Overbaugh; Nancy L Haigwood
Journal:  Vaccine       Date:  2012-06-27       Impact factor: 3.641

10.  Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge.

Authors:  N A Doria-Rose; C Ohlen; P Polacino; C C Pierce; M T Hensel; L Kuller; T Mulvania; D Anderson; P D Greenberg; S-L Hu; N L Haigwood
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.